{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:30:51Z","timestamp":1788546651355,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jchromb.2024.124425","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:42:36Z","timestamp":1733848956000},"page":"124425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effect of furmonertinib on the pharmacokinetics of rivaroxaban or apixaban in vivo"],"prefix":"10.1016","volume":"1251","author":[{"given":"Zhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124425_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.jchromb.2024.124425_b0010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jchromb.2024.124425_b0015","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous thromboembolism and prognosis in cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jchromb.2024.124425_b0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jchromb.2024.124425_b0025","first-page":"293","article-title":"Treatment of cancer associated thrombosis: Which role for direct oral anticoagulants in 2018?","volume":"43","author":"Frere","year":"2018","journal-title":"J Med Vasc"},{"key":"10.1016\/j.jchromb.2024.124425_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006468.pub6","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev 6"},{"key":"10.1016\/j.jchromb.2024.124425_b0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jchromb.2024.124425_b0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?","volume":"145","author":"Khorana","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jchromb.2024.124425_b0045","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jchromb.2024.124425_b0050","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1002\/onco.13584","article-title":"Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats","volume":"26","author":"O'Connell","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jchromb.2024.124425_b0055","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-Drug Interactions with Direct Oral Anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2024.124425_b0060","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1002\/onco.13596","article-title":"Update on Guidelines for the Management of Cancer-Associated Thrombosis","volume":"26","author":"Streiff","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jchromb.2024.124425_b0065","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2024.124425_b0070","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jchromb.2024.124425_b0075","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2024.124425_b0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jchromb.2024.124425_b0085","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1060028020960037","article-title":"Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis","volume":"55","author":"Dong","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jchromb.2024.124425_b0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124425_b0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2024.124425_b0100","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2024.124425_b0105","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2024.124425_b0110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jchromb.2024.124425_b0115","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jchromb.2024.124425_b0120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12959-021-00326-2","article-title":"The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines","volume":"19","author":"Alsubaie","year":"2021","journal-title":"Thromb. J."},{"issue":"2021","key":"10.1016\/j.jchromb.2024.124425_b0125","first-page":"209","article-title":"GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jchromb.2024.124425_b0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.lungcan.2003.09.001","article-title":"Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial","volume":"43","author":"Dancey","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jchromb.2024.124425_b0135","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2024.124425_b0140","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jtho.2016.05.008","article-title":"The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016","volume":"11","author":"Tan","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jchromb.2024.124425_b0145","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2024.124425_b0150","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jchromb.2024.124425_b0155","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2024.124425_b0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2024.124425_b0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2024.124425_b0170","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jchromb.2024.124425_b0175","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2024.124425_b0180","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s40265-021-01588-w","article-title":"Furmonertinib: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jchromb.2024.124425_b0185","first-page":"1019","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study, Lancet","volume":"10","author":"Shi","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.jchromb.2024.124425_b0190","article-title":"Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124425_b0195","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jtho.2022.07.1143","article-title":"Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study","volume":"17","author":"Shi","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jchromb.2024.124425_b0200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12916-023-02865-z","article-title":"Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies","volume":"21","author":"Hu","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.jchromb.2024.124425_b0205","doi-asserted-by":"crossref","unstructured":"S.S. Zhang and S.I. Ou, Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, \u201cuncommon-G719X, S768I, L861Q\u201d) Among the Third-Generation EGFR TKIs? Lung Cancer (Auckl) 13 (2022) 67-73, doi: 10.2147\/LCTT.S385437.","DOI":"10.2147\/LCTT.S385437"},{"key":"10.1016\/j.jchromb.2024.124425_b0210","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/s41401-021-00798-y","article-title":"Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model","volume":"43","author":"Zou","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jchromb.2024.124425_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2024.153903","article-title":"Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib","volume":"507","author":"Zhou","year":"2024","journal-title":"Toxicology"},{"key":"10.1016\/j.jchromb.2024.124425_b0220","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41401-020-0389-3","article-title":"Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer","volume":"41","author":"Liu","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jchromb.2024.124425_b0225","unstructured":"Shanghai Allis Medical Technology Co. L. Jiahuangsuan Fumeitini Pian Yaopin Shuomingshu [Drug instruction of Furmonertinib Mesilate Tablets]. 2021; https:\/\/www.allist.com.cn\/upload\/202109\/03\/202109031700252412.pdf. Accessed Oct 19, 2021."},{"key":"10.1016\/j.jchromb.2024.124425_b0230","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2024.124425_b0235","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124425_b0240","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-981-13-7647-4_5","article-title":"Transporter-mediated drug-drug interactions and their significance","volume":"1141","author":"Liu","year":"2019","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.jchromb.2024.124425_b0245","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719863641","article-title":"Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome","volume":"13","author":"Zhang","year":"2019","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"10.1016\/j.jchromb.2024.124425_b0250","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2024.124425_b0255","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.jchromb.2024.124425_b0260","doi-asserted-by":"crossref","unstructured":"T. Zhao, X. Li, Y. Chen, Du J, X. Chen, D. Wang, L. Wang, S. Zhao, C. Wang, Q. Meng, H. Sun, K. Liu and J. Wu, Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2\/3A4 and BCRP\/P-gp, Front Pharmacol 13 (2022) 914842, doi: 10.3389\/fphar.2022.914842.","DOI":"10.3389\/fphar.2022.914842"},{"key":"10.1016\/j.jchromb.2024.124425_b0265","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/dmd.116.073890","article-title":"Application of static modeling --in the prediction of in vivo drug-drug interactions between rivaroxaban and antiarrhythmic agents based on in vitro inhibition studies","volume":"45","author":"Cheong","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jchromb.2024.124425_b0270","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bcp.12541","article-title":"Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor","volume":"79","author":"Frost","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124425_b0275","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/bcp.12393","article-title":"Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban","volume":"78","author":"Frost","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124425_b0280","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10557-020-07129-z","article-title":"Identifying the dominant contribution of human cytochrome P450 2J2 to the metabolism of rivaroxaban, an oral anticoagulant","volume":"36","author":"Zhao","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jchromb.2024.124425_b0285","article-title":"In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224004343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224004343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:57:23Z","timestamp":1736434643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224004343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":57,"alternative-id":["S1570023224004343"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124425","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of furmonertinib on the pharmacokinetics of rivaroxaban or apixaban in vivo","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124425"}}